Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics reported Q2 financial results featuring a net loss of $20.2 million and a solid cash position of $207.4 million, which management believes funds operations into the future. The company provided a clinical update on its RESTORE-FA trial for Friedreich ataxia, modifying the study to support registrational plans with 12-week data expected in Q1 2027, and initiated dosing in a Phase 1 trial for DT-818 in myotonic dystrophy.
Key figures
- Net loss
- 20165000
- Ga expenses
- 5789000
- Dt 168 phase
- Phase 2
- Dt 818 phase
- Phase 1
- Rnd expenses
- 16388000
- Cash position
- 207396000
- Shares outstanding
- 62505340
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.